AstraZeneca suspends Motavizumab development
Motavizumab is an investigational monoclonal antibody that was being considered to help prevent RSV disease. AstraZeneca has requested withdrawal of the biological license application (BLA) pending at the
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.
The preclinical collaboration is being conducted with Marina Konopleva, associate professor in the Department of Leukemia at MD Anderson Cancer Center. The research collaboration will focus on characterizing